Study of seroprevalence in health personnel: Relation of vaccination with the presence of previous infection by SARS-COV-2 in the context of the national vaccination campaign for coronavirus after the first dose of the Gam-COVID-VAc vaccine (Sputnik -V).

• Autor(a) principal: Tortosa, Fernando
• Data de Publicação: 2021
• Outros Autores: Parodi, Victor, Carrasco, Gabriela, Barrientos, Luis, Barriera, Azul, Spano, Andrea, Gonzalez, Mirian, Roma, Vicente, Escudero, Sebastián, Lossetti, Lucia, Sartor, Marcia, Laspina, Sara
• Tipo de documento: preprint
• Idioma: spa
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/1790
• topic: Sputnik-V; Seroprevalencia; Personal de salud; COVID-19; SARS-COV-2; Vacuna coronavirus; coronavirus; Health Personnel; Coronavirus vaccine; seroprevalence; Sputnik-V; coronavirus; SARS-COV-2

In the context of the vaccination campaign for health personnel at high risk of exposure to SARS-COV-2 with the Sputnik-V vaccine, a study of seroprevalence of antibodies is proposed through the lateral flow test (Test of IgM and IgG antibodies of lateral flow type. COVID19 IgG / IgM Rapid Test from Orient Gene Biotech) in individuals who have or have not received the Sputnik-V vaccine. During the months of January to March 2021 in all health personnel who voluntarily give their consent, after at least 21 days after the first dose of the vaccine and in personnel who have not been vaccinated, the detection will be carried out qualitative antibody test with the lateral flow test (COVID19 IgG / IgM Rapid Test from Orient Gene Biotech), also recording previous RT-PCR, previous serology with IgG with a similar method, vaccination and seroconversion attributable to the first vaccination dose. Episodes of new infection will also be recorded in the period from 7 days after vaccination and during the follow-up period. The main objective of this work is to detect the prevalence of antibodies to SARS-COV-2 in health personnel with high exposure after the first dose of the Sputnik-V vaccine, as well as in unvaccinated personnel and its relationship with a previous confirmed infection for SARS -COV-2.